SPIN1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL20028315	0.68	11/20
SCHEMBL20028313	0.67	11/20
SCHEMBL17106554	0.77	10/20
SCHEMBL17106566	0.78	9/20
SCHEMBL17106569	0.77	9/20
SCHEMBL17106573	0.77	9/20
SCHEMBL17106564	1.00	8/20
SCHEMBL20028041	0.96	8/20
SCHEMBL20028317	0.85	8/20
SCHEMBL20028318	0.81	8/20
SCHEMBL17106572	0.79	8/20
SCHEMBL17106579	0.70	8/20
SCHEMBL17106589	0.68	8/20
SCHEMBL20028040	0.66	8/20
SCHEMBL17106552	0.65	8/20
SCHEMBL17106563	0.64	8/20
SCHEMBL19462583	0.46	8/20
SCHEMBL19461955	0.44	8/20
SCHEMBL19462125	0.44	8/20
SCHEMBL20028099	0.74	7/20

Clinical trials — most relevant to SPIN1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer	PHASE3	COMPLETED
S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer	PHASE3	COMPLETED
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment	PHASE2/PHASE3	RECRUITING
Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.	PHASE3	WITHDRAWN
S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）	PHASE3	RECRUITING
Study of S-1 in Combination With Radiotherapy in Esophageal Cancer	PHASE2	COMPLETED
S-1 and Radiotherapy for Elderly Esophageal Cancer Patients	PHASE2	WITHDRAWN
Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer	PHASE2	COMPLETED
Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer	PHASE2	UNKNOWN
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
Hereditary Sensory Neuropathy Serine Trial	PHASE2	UNKNOWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Study of Synapsis and Recombination in Male Meiosis and the Implications in Infertility	nan	COMPLETED
Combination of SBRT With Sequential S-1 for Treating Locally Advanced Pancreatic Cancer	nan	COMPLETED
Genetic Study of Idiopathic Scoliosis in a Cohort of Families (SCOGEN)	nan	UNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
The Natural History of Patients With Mutations in SEPN1 (SELENON) or LAMA2	nan	COMPLETED
Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Mechanisms of Cell Death in Spinal Muscular Atrophy	nan	COMPLETED
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy	nan	UNKNOWN
DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings	nan	COMPLETED
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Pancreatic Cancer Early Detection Program	nan	UNKNOWN
Newborn Screening for Spinal Muscular Atrophy (SMA) - a Proof of Principle Study Using Anonymised Blood Spots.	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SPIN1 binder may also engage these)

Protein	Name	Similarity
Q5R997	—	1.000	Q5R997 →
Q61142	—	1.000	Q61142 →
Q4V8J7	—	1.000	Q4V8J7 →
Q90WG2	—	1.000	Q90WG2 →
Q90WG1	—	1.000	Q90WG1 →
Q99865	—	0.994	Q99865 →
SPIN2B	Spindlin-2B	0.992	landscape →
Q5RA80	—	0.991	Q5RA80 →
Q5RAW7	—	0.988	Q5RAW7 →
SPIN3	Spindlin-3	0.988	landscape →
Q6NVE3	—	0.957	Q6NVE3 →
Q8L5Y9	—	0.940	Q8L5Y9 →
Q2KI39	—	0.939	Q2KI39 →
Q9Y2S7	—	0.938	Q9Y2S7 →
Q80U70	—	0.936	Q80U70 →
Q148V7	—	0.935	Q148V7 →
SUZ12	Polycomb protein SUZ12	0.934	landscape →
Q504Q3	—	0.934	Q504Q3 →
P11497	—	0.934	P11497 →
Q9TTS3	—	0.933	Q9TTS3 →
Q00PJ0	—	0.933	Q00PJ0 →
Q5ZMQ0	—	0.933	Q5ZMQ0 →
Q5SWU9	—	0.933	Q5SWU9 →
Q28559	—	0.933	Q28559 →
Q2IBD0	—	0.932	Q2IBD0 →
A4D7R9	—	0.932	A4D7R9 →
Q07DY8	—	0.931	Q07DY8 →
Q2IBA8	—	0.931	Q2IBA8 →
B5KFI0	—	0.931	B5KFI0 →
A0M8S0	—	0.931	A0M8S0 →